๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Weifang
Clinical trial register · China

Clinical Trials in Weifang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Weifang

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.
NCT07496177T2DM, CKD
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Phase 2
75
Weifang
2026-07-09
Not yet open
TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
NCT07714980Gastric Cancer (GC), Stomach Neoplasms
The Affiliated Hospital of Qingdao University
Not applicable
300
Dongying, Qingdao, Rizhao, Weifang, Weihai, Yantai
2026-07
Recruiting
Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion
NCT07552610Acute Ischemic Stroke, Large Vessel Occlusion, Thrombectomy, Neutrophil Extracellular Trap Formation
Xuanwu Hospital, Beijing
Not applicable
868
Weifang, Beijing
2026-06-22
Recruiting
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)
NCT07379190Stroke, Acute, Stroke, Ischemic, Cerebral Infarction
Weifang Medical University
Phase 3
458
Weifang
2026-06-22
Recruiting
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
NCT07692165Ulcerative Colitis (UC)
Innatus Therapeutics (Shanghai) Co., Ltd.
Phase 1/2
24
Guangzhou, Shenyang, Beijing, Hangzhou, Shanghai, Taiyuan, Weifang, Wenzhou
2026-06-11
Not yet open
Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion
NCT07670338Malignant Pleural Effusions (Mpe)
Shanghai Chest Hospital
Not applicable
308
Wuhan, Xinxiang, Weifang, Shanghai
2026-06-01
Not yet open
Digital Health Intervention for Early Identification and Prevention of Gestational Diabetes Mellitus
NCT07499622Gestational Diabetes Mellitus (GDM)
Peking University
Not applicable
1,200
Beijing, Weifang
2026-06
Recruiting
The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma
NCT07167342Colorectal Adenoma, Probiotics
The Affiliated Hospital of Qingdao University
Phase 4
294
Qingdao, Weifang
2026-05-22
Recruiting
Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation
NCT07556068Acute Ischemic Stroke, Cerebral Autoregulation
Beijing Shijitan Hospital, Capital Medical University
Observational
129
Beijing, Harbin, Dalian, Weifang
2026-04-20
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Recruiting
Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours
NCT07253181Acute Ischemic Stroke, Large Vessel Occlusion, Transportation of Patients
Xuanwu Hospital, Beijing
Phase 3
572
Beijing, Weifang
2026-01-06
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
The Impact of Methylene Blue on the Quality of Recovery in Patients Undergoing Hemorrhoidectomy
NCT06747195Hemorrhoidectomy, Postoperative Analgesia
Qilu Hospital of Shandong University
Observational
290
Heze, Jinan, Weifang
2025-01-01
By invitation
INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
NCT06747832Small Cell Lung Cancer
Guangzhou Ruixin Biotechnological Co., LTD
Phase EARLY_PHASE1
10
Weifang
2024-12-15
Recruiting
Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
NCT06673602Cognitive Impairment, Intracerebral Hemorrhage
Qinhuangdao Hospital of Traditional Chinese Medicine
Phase 4
200
Beijing, Qinhuangdao, Kaifeng, Jinan, Weifang, Kunming
2024-11-04
Recruiting
Effects of Different Pressure Garments on Upper Extremity Sensorimotor Functions and Quality of Life After Stroke
NCT06587308Cerebral Vascular Accident (CVA)/Stroke
National University of Malaysia
Not applicable
165
Weifang
2024-10-08
Active, closed
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Hoffmann-La Roche
Observational
1,000
Shantou, Luoyang, Shiyan, Xuzhou, Fushun, Panjin, Shenyang, Weifang
2024-05-09
Recruiting
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Active, closed
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
NCT05642780Solid Tumor
Klus Pharma Inc.
Phase 2
240
Guangzhou, Nanning, Wuhan, Changsha, Changchun, Dalian, Weifang, Xiโ€™an
2023-01-17
Active, closed
Imaging Markers of High-Risk Plaque Phenotype for Predicting Post-PCI Outcomes
NCT07117084Coronary Artery Disease, Percutaneous Coronary Intervention (PCI), Atherosclerosis of Coronary Artery
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
2,000
Beijing, Taiโ€™an, Weifang
2021-01-01
Recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
NCT04906434Advanced Liver Cancer
Abbisko Therapeutics Co, Ltd
Phase 1
200
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Weifang, Haerbin
2020-02-26
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/weifang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Weifang.

How many clinical trials are recruiting in Weifang?

13 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Weifang), 21 studies
PhaseStudiesRecruitingShare
Not applicable6228.6%
Observational4219%
Phase 23214.3%
Phase 1229.5%
Phase 3229.5%
Phase 4229.5%
Phase 1/2114.8%
Phase EARLY_PHASE1104.8%

Most active sponsors

Lead sponsors with the most studies (Weifang)
Lead sponsorStudiesRecruiting
The Affiliated Hospital of Qingdao University21
Xuanwu Hospital, Beijing22
Abbisko Therapeutics Co, Ltd11
Beijing Shijitan Hospital, Capital Medical University11
BeOne Medicines11
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.11
Chinese Academy of Medical Sciences, Fuwai Hospital10
Guangzhou Ruixin Biotechnological Co., LTD10
Harbin Medical University10
Hoffmann-La Roche10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.